First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis

BACKGROUND: Currently, in Belgium, bevacizumab is reimbursed for ovarian cancer patients, based on a contract between the Minister and the manufacturer including confidential agreements. This reimbursement will be re-evaluated in 2018. OBJECTIVE: To support the reimbursement reassessment by calculat...

Descripción completa

Detalles Bibliográficos
Autores principales: Neyt, Mattias, Vlayen, Joan, Devriese, Stephan, Camberlin, Cécile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891000/
https://www.ncbi.nlm.nih.gov/pubmed/29630612
http://dx.doi.org/10.1371/journal.pone.0195134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891000/
https://www.ncbi.nlm.nih.gov/pubmed/29630612
http://dx.doi.org/10.1371/journal.pone.0195134

Ejemplares similares